BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
We would like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on July 26, 2023, has approved the allotment of 57,750 equity shares of face value of Re. 1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 (''Bliss GVS ESOP-2019''). BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copies of the newspaper advertisement of the notice published in The Free Press Journal (English) and Navshakti (Regional) on July 25, 2023, concerning the proposed transfer of unclaimed final dividend 2015-2016 and its corresponding shares to IEPF Authority, pursuant to section 124(6) of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time. BLISS GVS PHARMA LTD. - 506197 - Notice To Shareholders W.R.T. Transfer Of Unclaimed Final Dividend 2015-2016 And Its Corresponding Shares To Investor Education And Protection Fund (IEPF) Authority
In accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose a copy of the communication sent to those concerned shareholders, whose dividend have remained unclaimed for a period of seven consective years or more, concerning the proposed transfer of unclaimed fina dividend 2015-2016 and its corresponding shares to the IEPF Authority in pursuance of section 124(6) of the Companies Act, 2013 read with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016. BLISS GVS PHARMA LTD. - 506197 - Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2023
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2023 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2023. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Internal Procedures and Conduct for Regulating, Monitoring, and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01, 2023, and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30, 2023. BLISS GVS PHARMA LTD. - 506197 - Clarification On Price Movement
Please find enclosed herewith Clarification Letter regarding Price movement sought by BSE Limited. BLISS GVS PHARMA LTD. - 506197 - Disclosure Of Voting Results Of The 38Th Annual General Meeting Of Bliss GVS Pharma Limited Held On July 19, 2023 Along With Scrutinizer'S Report
In accordance with the Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the voting results of 38th Annual General Meeting of the Company held on Wednesday, July 19, 2023 in the prescribed format along with the report of the Scrutinizer on remote e-voting and e-voting at the 38th Annual General Meeting. BLISS GVS PHARMA LTD. - 506197 - Proceedings Of 38Th Annual General Meeting Of The Company
Please find enclosed herewith proceedings of the 38th Annual General Meeting held on Wednesday, July 19, 2023 at 11:00 a.m. through Video Conferencing ("VC")/Other Audio-Visual Means ("OVAM"). BLISS GVS PHARMA LTD. - 506197 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Please find enclosed herewith Outcome of 38th Annual General Meeting ("AGM") of the Company held today i.e. Wednesday, July 19, 2023. BLISS GVS PHARMA LTD. - 506197 - Clarification sought from Bliss GVS Pharma Ltd
The Exchange has sought clarification from Bliss GVS Pharma Ltd on July 18, 2023 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2023.